Insulin response to oral glucose loading and coronary artery disease in nondiabetics

International Heart Journal

Volumn 46, Issue 5, 2005, Pages 761-770

  Karabulut, Aziz ^a   Iltumur, Kenan ^a   Toprak, Nizamettin ^a   Tuzcu, Alpaslan Kemal ^a   Kara, Ismail Hamdi ^a   Kaplan, Abdurrahman ^a   Aksu, Yasin ^b  

^a DICLE UNIVERSITY   (Turkey)

^b Diyarbakir Hospital for Children   (Turkey)

Author keywords

Postprandial hyperinsulinemia; Severity of coronary artery disease

Indexed keywords

GLUCOSE; INSULIN; LIPID;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESPONSE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; GLUCOSE TOLERANCE TEST; HOSPITALIZATION; HYPERINSULINISM; HYPERTENSION; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RADIOGRAPHY; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERINSULINISM; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33644873630     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.46.761     Document Type: Article

References (37)

1. Khan SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjecs. Evidence for a hyperbolic function. Diabetes 1993; 42: 1663-72.
2. Haffher SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 1999; 84: 11J-4. (Review)
3. Reusch JE. Current concepts in insulin resistance, type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiol 2002; 90:19G-26. (Review)
4. Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol 2002; 90: 27G-33. (Review)
5. Goldstein BJ. Insulin resistance and core defect in type 2 diabetes mellitus Am J Cardiol 2002; 90: 3G-10.
6. Onat A, Ceyhan K, Sansoy V, et al. Fasting insulin levels independently associated with coronary heart disease in non-diabetic Turkish men and women. Int J Cardiol 2002; 86: 61-9.
7. Zilversmit DB. Atherogenesis: A postprandial. phenomenon. Circulation 1979; 60: 473-85.
8. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: Metabolic factors associated with cardiovascular disease. Diabetologia 2002; 45:461-75. (Review)
9. Spallarossa P, Barsotti A, Cordera R, Ghigliotti G; Maggi D, Brunielli C. Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy J Endocrinol Invest 2004; 27: 485-95. (Review)
10. Patsch W, Esterbauer H, Foger B, Patsch JP. Postprandial lipemia and coronary risk. Curr Atheroscler Rep 2001; 2:232-42. (Review)
11. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990; 119: 1262-7.
12. Negri M, Sheiban I, Arigliano P, et al. Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor-1. Am J Cardiol 1993; 72: 397-401.
13. Birnie DH, Holme ER, McKay IC, Hood S, McColl KE, Hillis WS. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 1998; 19: 387-94.
14. Gensini GG Coronary Arteriography. Mount Kisco, New York: Futura Publishing Co; 1975.
15. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 Jul; 28: 412-9.
17. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1997; 20: 935-42.
18. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-60.
19. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policeman Study. Circulation 1998; 98: 398-404.
20. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study 10 years later. Horm Metab Res Suppl 1985; 15: 41-6.
21. Perry IJ, Wannamethee SG, Whincup PH, Shaper AG, Walker MK, Alberti KG. Serum insulin and incident coronary heart disease in middle-aged British man. Am J Epidemiol 1996; 144: 224-34.
22. Yarnell JW, Sweetnam PM, Marks V, Teale JD, Bolton CH. Insulin in ischaemic heart disease: Are associations explained by triglycende concentrations? The Caerphilly prospective study. Br Heart J 1994; 171: 293-6.
23. Wingard DL, Barrett-Connor EL, Farrara A. Is insulin really a heart disease risk factor. Diabetes Care 1995; 18: 1299-304. (Review)
24. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004; 110: 803-9.
25. Ozsahin AY, Gokcel A, Sezgin N, et al. Prevalence of the metabolic syndrome in a Turldsh adult population. Diabetes Nutr Metab 2004; 17: 230-4.
26. Ford ES, Giles WH, Dietz WH. Prevalance of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
27. Tillin T, Forouhi N, Johnston DG McKeigue PM, Chaturvedi N, Godsland IF. Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: A UK population-based cross-sectional study. Diabetologia. 2005; 48: 649-56.
28. Homma Y. Predictors of atherosclerosis. J Atheroscler Thromb 2004; 11: 265-70.
29. Turhan H, Yasar AS, Basar N, Bicer A, Erbay AR, Yetkin E. High prevalence of metabolic syndrome among young women with premature coronary artery disease. Coron Artery Dis 2005; 16: 37-40.
30. Ariza CR, Frati AC, Gomez G, Almazan A. Hyperinsulinemia in patients with coronary heart disease in absence of overt risk factors. Arch Med Res 1997; 28: 115-9.
31. Agata J, Miyazaki Y, Takada M, et al. Association of insulin resistance and hyperinsulinemia with disturbed lipid metabolism in patients with essential hypertension. Hypertens Res 1998; 21: 57-62.
32. El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 2004; 15: 2816-27. (Review)
33. Davis CL, Kapuku G, Snieder H, Kumar M, Treiber FA. Insulin resistance syndrome and left ventricular mass in healthy young people. Am J Med Sci 2002; 324: 72-5.
34. Koistinen HA, Zierath JR. Skeletal muscle insulin resistance: Is it important for the pathogenesis of type 2 diabetes after all? J Endocrinol Invest 2003; 26: 690-2.
35. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64: 2537-65. (Review)
36. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
37. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-31.